Hims & Hers Health (NYSE:HIMS) Stock: Insider Oluyemi Okupe Sells 3,518 Shares

Hims & Hers Health, Inc. (NYSE:HIMS – Get Free Report) CFO Oluyemi Okupe sold 3,518 shares of the firm’s stock in a transaction that occurred on Tuesday, November 17th. The shares were sold at an average price of $18.53, for a total value of $65,188.54. Following the completion of the transaction, the chief financial officer owned 266,188 shares of the company’s stock, valued at approximately $4,932,463.64. The trade was a 1.30% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Oluyemi Okupe also recently made the following trade(s):

  • On Thursday, October 1st, Oluyemi Okupe sold 2,000 shares of Hims & Hers Health stock. The shares were sold at an average price of $29.70, for a total value of $59,400.00.
  • On Tuesday, September 22nd, Oluyemi Okupe sold 29,277 shares of Hims & Hers Health stock. The shares were sold at an average price of $29.95, for a total transaction of $876,846.15.
  • On Thursday, September 17th, Oluyemi Okupe sold 12,313 shares of Hims & Hers Health stock. The shares were sold at an average price of $28.82, for a total value of $354,860.66.

Hims & Hers Health Price Performance

HIMS opened at $16.02 on Friday. The firm has a market cap of $3.76 billion, a PE ratio of -19.30 and a beta of 2.53. The company has a debt-to-equity ratio of 3.85, a current ratio of 0.92 and a quick ratio of 0.84. Hims & Hers Health, Inc. has a 1 year low of $13.74 and a 1 year high of $40.99. The stock has a 50-day moving average price of $26.77 and a 200-day moving average price of $26.49.

Hims & Hers Health (NYSE:HIMS – Get Free Report) last announced its quarterly earnings results on Monday, November 9th. The company reported $0.03 earnings per share for the quarter, missing the consensus estimate of $0.06 by ($0.03). Hims & Hers Health had a negative net margin of 6.65% and a negative return on equity of 9.62%. The firm had revenue of $890.37 million for the quarter, compared to the consensus estimate of $893.13 million. During the same period last year, the business earned $0.06 EPS. Hims & Hers Health’s revenue was up 48.6% on a year-over-year basis. Sell-side analysts predict that Hims & Hers Health, Inc. will post -0.38 earnings per share for the current fiscal year.

Top Hims & Hers Health Stories

These are some of the HIMS stories that stood out recently:

  • Positive Sentiment: Peptides+ launches with five treatments, including sermorelin, glutathione and NAD+, offered through a clinically guided program. The expansion could broaden Hims & Hers’ services and create another source of customer and revenue growth as interest in peptides rises. Peptides+ launch announcement
  • Neutral Sentiment: The initial treatments are compounded and are not FDA-approved; the company says more needs to be learned about their efficacy. This creates uncertainty around consumer demand and the launch’s longer-term prospects. CNBC coverage of peptide treatments
  • Negative Sentiment: Two insiders reported share sales: CFO Oluyemi Okupe sold 3,518 shares, while Deborah Autor sold 23,828 shares. Both transactions were made under pre-arranged Rule 10b5-1 plans, which may reduce their significance as a signal, though insider selling can still weigh on sentiment. Insider sale report

Analysts Set New Price Targets

A number of equities research analysts have weighed in on the stock. JPMorgan Chase & Co. started coverage on shares of Hims & Hers Health in a research note on Friday, September 11th. They set a “neutral” rating and a $32.00 target price for the company. Deutsche Bank upped their price target on shares of Hims & Hers Health from $25.00 to $26.00 and gave the company a “hold” rating in a research report on Tuesday, August 11th. TD Cowen raised their price objective on shares of Hims & Hers Health from $25.00 to $30.00 and gave the stock a “hold” rating in a report on Tuesday, August 11th. Needham & Company LLC decreased their target price on Hims & Hers Health from $42.00 to $32.00 and set a “buy” rating on the stock in a report on Tuesday, November 10th. Finally, Citigroup reduced their price target on Hims & Hers Health from $35.00 to $33.00 and set a “neutral” rating for the company in a research report on Tuesday, August 11th. Three analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, Hims & Hers Health currently has an average rating of “Hold” and a consensus target price of $31.53.

Check Out Our Latest Stock Report on Hims & Hers Health

Hedge Funds Weigh In On Hims & Hers Health

Institutional investors and hedge funds have recently made changes to their positions in the business. Blue Jean Financial LLC bought a new position in Hims & Hers Health in the third quarter worth approximately $3,159,000. B. Metzler seel. Sohn & Co. AG bought a new stake in shares of Hims & Hers Health in the 2nd quarter valued at about $2,992,000. FirstWave Capital Management LLC boosted its stake in Hims & Hers Health by 30.6% in the second quarter. FirstWave Capital Management LLC now owns 339,978 shares of the company’s stock valued at $11,787,000 after acquiring an additional 79,731 shares in the last quarter. Concurrent Investment Advisors LLC lifted its holdings in shares of Hims & Hers Health by 109.8% during the 2nd quarter. Concurrent Investment Advisors LLC now owns 35,272 shares of the company’s stock valued at $1,223,000 after purchasing an additional 18,459 shares during the last quarter. Finally, Prosperitas Financial LLC acquired a new position in Hims & Hers Health during the 3rd quarter valued at about $2,649,000. 63.52% of the stock is owned by hedge funds and other institutional investors.

Hims & Hers Health Company Profile

(Get Free Report)

Hims & Hers Health, Inc. operates a consumer-focused telehealth platform that connects patients with licensed healthcare providers and offers access to treatments and wellness products. Its services include online consultations, prescription care and over-the-counter products. The company serves a range of health needs, including hair loss, sexual health, skin care, mental health and weight management. Its platform also offers primary care and other services, with offerings varying by location and individual eligibility.

Read More

Insider Buying and Selling by Quarter for Hims & Hers Health (NYSE:HIMS)

Receive News & Ratings for Hims & Hers Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hims & Hers Health and related companies with MarketBeat.com's FREE daily email newsletter.